Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Amortizatization of Intangibles (2017 - 2023)

Rein Therapeutics (RNTX) has disclosed Amortizatization of Intangibles for 7 consecutive years, with -$188000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Amortizatization of Intangibles fell 252.85% to -$188000.0 in Q4 2023 year-over-year; TTM through Sep 2024 was -$188000.0, a 167.38% decrease, with the full-year FY2023 number at -$32000.0, down 115.38% from a year prior.
  • Amortizatization of Intangibles was -$188000.0 for Q4 2023 at Rein Therapeutics, down from $1000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $123000.0 in Q4 2022 to a low of -$188000.0 in Q4 2023.
  • A 5-year average of $8800.0 and a median of $12000.0 in 2020 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: plummeted 1400.0% in 2021, then surged 3333.33% in 2023.
  • Rein Therapeutics' Amortizatization of Intangibles stood at $61000.0 in 2019, then crashed by 116.39% to -$10000.0 in 2020, then crashed by 180.0% to -$28000.0 in 2021, then soared by 539.29% to $123000.0 in 2022, then tumbled by 252.85% to -$188000.0 in 2023.
  • Per Business Quant, the three most recent readings for RNTX's Amortizatization of Intangibles are -$188000.0 (Q4 2023), $1000.0 (Q3 2023), and $52000.0 (Q2 2023).